RBC Capital maintains Regeneron stock Outperform rating

RBC Capital Markets reiterated its Outperform rating for Regeneron (REGN) with a $943 price target, driven by optimism surrounding Phase III trial results for itepekimab, a COPD treatment candidate with a potential $6B peak revenue. Positive data could shift investor focus from Eylea revenue concerns and lead to stock appreciation, while recent developments include Regeneron's acquisition of 23andMe's assets for $256M and a $406.8M antitrust win against Amgen. Citi also upgraded Regeneron to Buy with a $700 price target, citing the strength of Regeneron's pipeline.

Analysis

RBC Capital Markets maintains a positive outlook on Regeneron Pharmaceuticals (NASDAQ:REGN), reiterating an Outperform rating and a $943.00 price target, supported by the company's current P/E ratio of 14.2x, which InvestingPro data suggests is attractive relative to its Fair Value estimates. A key impending catalyst is the Phase III study results for itepekimab, a COPD drug candidate. Analyst Brian Abrahams anticipates itepekimab could significantly reduce COPD exacerbations, projecting an unadjusted global peak revenue of $6 billion and a probability of success (PoS)-adjusted revenue exceeding $3.5 billion, even with conservative market penetration. RBC estimates a 65% chance of a 5-15% upside for Regeneron's stock contingent on positive itepekimab data, which could also mitigate investor concerns over the revenue erosion of Eylea and potentially align the stock value closer to RBC's DCF-based fair value. Regeneron, with a market capitalization of $63 billion and $14.1 billion in annual revenue, demonstrates strong financial health, evidenced by an InvestingPro "GREAT" rating and a balance sheet showing more cash than debt. Recent strategic developments further bolster Regeneron's prospects: the successful $256 million bid for 23andMe's assets is set to enhance its genetics-guided research, and a significant legal victory saw Amgen ordered to pay Regeneron $406.8 million in an antitrust case concerning cholesterol medication Praluent. Complementing RBC's view, Citi upgraded Regeneron from Neutral to Buy, increasing its price target to $700, citing the robustness of Regeneron's pipeline, particularly in melanoma and COPD.

Key Decisions for Investors

• Investors should closely monitor the upcoming Phase III trial results for itepekimab, as positive outcomes are a significant near-term catalyst with potential for substantial stock appreciation and a shift in narrative away from Eylea revenue concerns.
• Given the reiterated Outperform rating from RBC Capital with a $943 price target, Citi's upgrade to Buy with a $700 target, Regeneron's attractive P/E ratio of 14.2x, and recent positive developments including strategic acquisitions and legal victories, investors may find the current valuation compelling for potential upside.
• Consider the potential for itepekimab to unlock significant new revenue streams, estimated at over $3.5 billion PoS-adjusted, which could contribute to a re-rating of the stock if the anticipated 65% probability of a 5-15% upside post-data release materializes.
• Evaluate Regeneron's enhanced R&D capabilities following the 23andMe asset acquisition and its strengthened competitive position post the favorable antitrust ruling against Amgen as factors potentially de-risking future growth and supporting long-term value.